Open access
Sep 2026
Tumour Mutation Burden Does Not Predict Immune Cell Frequency or Risk of Recurrence After Surgery in Hepatocellular Carcinoma
Introduction/Objectives: Understanding the genetic and immune heterogeneity in hepatocellular carcinoma (HCC) is critical for accurate pathological characterisation and treatment planning, as therapies advance towards personalisation. Tumour mutational burden (TMB) has been proposed as a biomarker of response to immune...
Abigail Connor, Leon Chang, E. West et al.
· Cancers · 0 citations